EUVIMEDEUVIMED entdecken
CrossrefInfokarte

TDP‐43 Phosphorylation: Pathological Modification or Protective Factor Antagonizing TDP‐43 Aggregation in Neurodegenerative Diseases?

Simone Mosna, Dorothee Dormann

BioEssays · 2026-01 · 48 (1)

DOI: 10.1002/bies.70084 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT TDP‐43 is a ubiquitously expressed RNA‐binding protein that aggregates in the brains of patients suffering from neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and Alzheimer's disease. Aggregated TDP‐43 in these diseases is hyperphosphorylated in its C‐terminal intrinsically disordered region, while physiological TDP‐43 is normally unphosphorylated. Whether TDP‐43 phosphorylation is a pathological driver, or rather a protective antagonist of TDP‐43 aggregation and consequently neurodegeneration, is still debated and a matter of ongoing research. Here, we review current knowledge about TDP‐43 phosphorylation in disease and the kinases and phosphatases that regulate this post‐translational modification. We discuss how TDP‐43 phosphorylation is thought to shape TDP‐43's phase separation, aggregation and toxicity in neurodegenerative diseases. We highlight recent research that provides evidence that hyperphosphorylation antagonizes TDP‐43 phase separation and aggregation, and speculate about a potential role of condensates in TDP‐43 phosphorylation.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →